From single-marker to multi-marker specifications

The commercial framing of botanical extract quality has, for most of the last decade, run on single-marker specifications. A working marker — eurycomanone for Tongkat Ali, bacosides for Bacopa, kavalactones for Kava, rosavins-and-salidroside for Rhodiola — quantified at a defined percentage band has been sufficient to clear material through procurement and into formulation. That model is now thinning out at the premium specification tier. This note sets out the direction of the shift and what it means for both sides of the procurement conversation.

Why the single marker worked

The single-marker model worked because it solved the practical problem in front of the industry through the 2010s: producing a Certificate of Analysis that a regulated buyer could clear without requiring full-spectrum chemotype work on every incoming batch. Eurycomanone at 1–2% on the COA for Tongkat Ali, bacosides at 20% for Bacopa, kavalactones at 30% for Kava — these became the working specifications because they were analytically tractable, the reference standards were available, and the regulators in the major export markets accepted them.

The model also worked because the demand-side buyer was, in most cases, a formulator with a moderate efficacy claim and a moderate analytical capability. Where the buyer's claim framework required only that the relevant marker be present at a defined band, the single-marker spec carried the procurement.

Why it is thinning

Three pressures have moved the working specification toward multi-marker frames. The first is the proliferation of clinical claims that depend on a specific chemotype profile rather than a single marker percentage. Bacopa's cognitive-claim formulations increasingly specify a bacoside ratio — bacopaside I and II at defined relative levels — rather than total bacosides. Eurycoma's energy and male-health formulations have begun to specify glycosaponin content alongside eurycomanone. Kava's noble-chemotype clearance now commonly specifies the relative levels of the six lead kavalactones rather than only their total.

The second pressure is the gap between batches that meet a single-marker specification but present materially different commercial profiles. Two Tongkat Ali batches at 1.5% eurycomanone can clear the same COA line and produce visibly different finished-product profiles because the rest of the quassinoid signature differs. Brands who have lived through a formulation re-run on this basis tend to upgrade their incoming specification permanently.

The third pressure is the analytical capability of the regulated buyer. Pharmaceutical R&D partners, dossier-led submission programmes, and the more analytically-mature supplement brands now have HPLC chemotype capability in-house or through contract laboratory access. Where the buyer can read a multi-marker chromatogram, the buyer specifies a multi-marker incoming standard.

What multi-marker actually looks like

A multi-marker specification on a botanical extract typically adds three layers to the single-marker COA line. The first is quantification of multiple lead compounds: bacopaside I, bacopaside II, bacoside A3, jujubogenin glycosides. The second is a documented ratio between those compounds: "bacopaside I:II ratio 1.4–1.8" rather than "bacosides ≥ 20%." The third is a chemotype fingerprint — typically an HPLC profile matched against a reference standard for the species and varietal.

For Eurycoma, the multi-marker direction commonly adds eurycomanone, glycosaponin, polysaccharide, and quassinoid-fingerprint lines. For Kava, the kavalactone ratio (the chemotype number) is the multi-marker form: a noble chemotype is defined by the relative levels of the six lactones, not just their sum. For Rhodiola, rosavins and salidroside are commonly specified independently along with documented chromatographic identity against R. rosea reference material.

The cost direction

Multi-marker analytical work is more expensive than single-marker per batch. The cost direction at programme level, however, is downward. A buyer with a stable supply programme and a multi-marker spec catches batch-level variation upstream of formulation, reduces failed-batch and reformulation cost, and produces a tighter finished-product profile that supports the clinical claim. The economics favour multi-marker specifications above a programme volume threshold; below that threshold, the single-marker spec remains the working model.

For suppliers, the practical implication is that the analytical infrastructure investment — multi-marker HPLC methods, validated reference standards, inter-laboratory comparison programmes — is no longer optional for premium-tier supply. Suppliers who lack this infrastructure are visible to the buyer immediately on the first technical exchange.

Where it goes

The direction of travel is continued refinement of multi-marker specifications, broader inter-laboratory analytical standardisation through the ISO 17025 partner laboratory matrix, and the gradual incorporation of biological-activity assays alongside chemical analysis for the ingredients where the activity-to-marker relationship is well-characterised. The single-marker COA line will persist in commodity supply; the conversation at the premium tier has moved beyond it.

Buyers approaching a new supplier should now treat the analytical question as a primary technical exchange rather than a procurement formality. The supplier's ability to articulate the multi-marker framework for the ingredient in question — and to supply method validation alongside results — is the working signal of analytical maturity.